« ALL INFRASTRUCTURE SERVICES

Biochemical and Cellular Assay

National facility

The Biochemical and Cellular Assay facility provide the drug discovery projects in the DDD platform with enzymatic and cellular assays using microplate based technologies. We support the drug discovery projects with analyze of the activity for newly synthesized molecules and biologicals in order to drive structure-activity explorations and thereby enabling the next round of design of a new molecular entities.

SERVICES

  • High throughput microplate based
    • Biochemical and Cell assays
    • Phenotypical cell assays
    • RNAi knock out using siRNA (Human)
  • Target validation.
  • Cellular profiling of drugs.
  • In vitro drug toxicity expertise.

EQUIPMENT

  • Labcyte ECHO550 non-contact liquid handler.
  • PerkinElmer Janus 3 arm liquid handler.
  • Envision plate reader.
  • BioTek cell washer, Flexdrop and Wellmate dispensers.
  • GE Cytell imager
  • Xcelligence RTCA 96 well
  • Fully equipped cell room for cell cultivation.
  • Chemical and 2 human genomic siRNA libraries.

RECENT PROJECTS

1: Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, et.al.. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21.

2: Schmidt L, Kling T, Monsefi N, Olsson M, Hansson C, Baskaran S, Lundgren B, Martens U, Häggblad M, Westermark B, Forsberg Nilsson K, Uhrbom L, Karlsson-Lindahl L, Gerlee P, Nelander S. Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro Oncol. 2013 Nov;15(11):1469-78.

3: Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, Hultin-Rosenberg L, Lundgren B, Martens U, Máthé G, Yakhini Z, Helou K, Krawiec K, Kanter L, Hjerpe A, Stål O, Linderholm BK, Lehtiö J. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:2175.